CGC vs. BCYC, NTLA, ZYME, RCKT, GYRE, PSTX, ADPT, OCS, AVXL, and NUVB
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Zymeworks (ZYME), Rocket Pharmaceuticals (RCKT), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Adaptive Biotechnologies (ADPT), Oculis (OCS), Anavex Life Sciences (AVXL), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.
Canopy Growth vs.
Canopy Growth (NASDAQ:CGC) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
Canopy Growth has a net margin of -186.17% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Canopy Growth's return on equity.
Canopy Growth presently has a consensus target price of $3.50, indicating a potential upside of 60.55%. Bicycle Therapeutics has a consensus target price of $34.50, indicating a potential upside of 158.62%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Canopy Growth.
In the previous week, Bicycle Therapeutics had 17 more articles in the media than Canopy Growth. MarketBeat recorded 18 mentions for Bicycle Therapeutics and 1 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.75 beat Bicycle Therapeutics' score of 0.46 indicating that Canopy Growth is being referred to more favorably in the media.
Bicycle Therapeutics has lower revenue, but higher earnings than Canopy Growth. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics received 118 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 70.41% of users gave Bicycle Therapeutics an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote.
Canopy Growth has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 1.3% of Canopy Growth shares are held by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Bicycle Therapeutics beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
This page (NASDAQ:CGC) was last updated on 1/18/2025 by MarketBeat.com Staff
